ERBB2 and breast cancer: Feng and colleagues found that CD36 acted as a key player in resistance to lapatinib in human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells, and inhibiting CD36 restored sensitivity to lapatinib and triggered apoptosis in those lapatinib-resistant cells (Feng et al., 2019).